Limb-Girdle Video Assessment
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT05528757 |
Recruitment Status :
Active, not recruiting
First Posted : September 6, 2022
Last Update Posted : May 31, 2023
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease |
---|
Limb-Girdle Muscular Dystrophy ; Subtypes 2A, 2B, and 2I |
Study Type : | Observational |
Actual Enrollment : | 45 participants |
Observational Model: | Cohort |
Time Perspective: | Prospective |
Official Title: | Limb-Girdle Video Assessment Concept Elicitation and Feasibility Study |
Actual Study Start Date : | June 20, 2022 |
Actual Primary Completion Date : | March 1, 2023 |
Estimated Study Completion Date : | January 31, 2024 |

Group/Cohort |
---|
LGMDs Patients
Patients with a genetically confirmed diagnosis of a LGMD subtype 2A, 2B, or 2I
|
- Assessing the fluctuation of movement abilities of LGMDs patients via remote video capture. [ Time Frame: January 2023 - March 2023 ]Using the newly developed LGVA Video Capture Manual, participants are asked to record two sets of videos of them performing assigned tasks. Participants will have one week to complete each round of video capture, with approximately one month between each round. Videos will be captured remotely and uploaded through a secure platform.
- Task Selection Survey [ Time Frame: August 2022 - September 2022 ]Electronic survey asking LGMDs patients about tasks and activities they perform in their daily life, and if/ how these are impacted by their LGMD symptoms.
- Focus Group [ Time Frame: September 2022 - October 2022 ]Small group discussion of participants with similar functional abilities to discuss the progression of symptoms and heterogeneity among subtypes.
- Exit Interview [ Time Frame: January 2023 - March 2023 ]After the feasibility video captures are complete, participants are asked about their experiences using the LGVA Video Capture Manual and the recording procedures.

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 14 Years and older (Child, Adult, Older Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Sampling Method: | Non-Probability Sample |
- Person with confirmed diagnosis of an LGMD 2A, 2B, or 2I
- ≥14 years of age at the timing of consent (if age 14 - 17, consent from the parent/ legal guardian is also needed)
- Able to read, speak, and understand English
- Residing in the USA
- Willing and able to complete an electronic survey, which includes questions about personal characteristics and medical history as well as review of tasks
- Willing and able to discuss their experiences as a person living with an LGMD in a group setting
- Willing and able to complete 2 rounds of video capture following instructions in the LGVA Video Capture Manual in a 30-day period
- Willing and able to complete an exit interview to discuss their experiences capturing and recording videos with the LGVA Video Capture Manual

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT05528757
United States, Massachusetts | |
Casimir | |
Kingston, Massachusetts, United States, 02360 |
Study Director: | Lauren Carroll | Casimir |
Responsible Party: | The Emmes Company, LLC |
ClinicalTrials.gov Identifier: | NCT05528757 |
Other Study ID Numbers: |
CAS-CAS008-01 |
First Posted: | September 6, 2022 Key Record Dates |
Last Update Posted: | May 31, 2023 |
Last Verified: | May 2023 |
Individual Participant Data (IPD) Sharing Statement: | |
Plan to Share IPD: | No |
Studies a U.S. FDA-regulated Drug Product: | No |
Studies a U.S. FDA-regulated Device Product: | No |
Limb-Girdle Muscular Dystrophy Outcome Measure Development Video Captures |
Remote Assessment Concept Elicitation Feasibility Testing |
Muscular Dystrophies Muscular Dystrophies, Limb-Girdle Muscular Disorders, Atrophic Muscular Diseases |
Musculoskeletal Diseases Neuromuscular Diseases Nervous System Diseases Genetic Diseases, Inborn |